To study of renal adverse effects of Tenofovir in HIV infected children on ART

Study of Renal Adverse Effects of Tenofovir Containing Regimen in HIV Infected Children

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2022/09/045278

Enrollment

Registered

2022-09-07

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B20- Human immunodeficiency virus [HIV]disease

Interventions

Intervention1: Nil: Nil

Eligibility

Inclusion criteria

Inclusion criteria: 1.All HIV infected children from age 10 years or weight more than 30 kg to 21 years of age receiving Tenofovir containing ART for at least 6 months 2.eGFR more than 60 ml/min/m2 3.Individuals whose base line parameters available before starting ART treatment

Exclusion criteria

Exclusion criteria: 1.History of Hypertension, Diabetes Mellitus, Congenital Heart disease, Chronic liver failure, Cardio Vascular Disease, Nephrotic syndrome. 2.Hepatitis B and C infection. 3.Transfer of care to other medical care facilities

Design outcomes

Primary

Measure	Time frame
1.Changes of eGFR from base line 2.Changes of serum creatinine from base line 3.Changes in creatinine clearance from base lineTimepoint: 3 months	—

Secondary

Measure	Time frame
1.Changes of CD4 count from base line 2.Changes of Serum phosphate during treatment 3.Proteinuria during treatmentTimepoint: 3 months	—

Countries

India

Contacts

Public ContactDr Ravindra Kumar

Moti Lal Nehru Medical College

mukeshvirsingh@gmail.com9456630304

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026